论文部分内容阅读
目的对比齐拉西酮与奥氮平治疗早期精神分裂症合并糖尿病患者的临床效果。方法选取医院2015年1月-2017年1月收治的早期精神分裂症合并糖尿病患者72例,根据随机数字表法均分为观察组与对照组各36例。观察组患者予以齐拉西酮治疗,对照组患者予以奥氮平治疗,对2组患者治疗前后的阳性与阴性症状量表(PANSS)评分、糖尿病有关指标予以统计比较。结果治疗前2组患者阳性症状、阴性症状及一般精神症状评分比较差异无统计学意义(P>0.05);治疗后观察组患者阳性症状、阴性症状及一般精神症状评分均低于对照组患者,差异均有统计学意义(P<0.05)。治疗前2组患者空腹血糖、餐后2h血糖及糖化血红蛋白水平比较差异无统计学意义(P>0.05);治疗后观察组患者空腹血糖、餐后2h血糖及糖化血红蛋白水平均低于对照组患者,差异均有统计学意义(P<0.05)。结论早期精神分裂症合并糖尿病患者应用齐拉西酮治疗的效果更加确切,能明显减轻患者临床症状,且不会影响患者血糖水平,优于奥氮平治疗,是一种值得临床全面应用与推广的治疗药物。
Objective To compare the clinical efficacy of ziprasidone and olanzapine in the treatment of early schizophrenia with diabetes mellitus. Methods Seventy-two patients with early schizophrenia with diabetes admitted to our hospital from January 2015 to January 2017 were randomly divided into observation group (36 cases) and control group (36 cases). The patients in the observation group were treated with ziprasidone. The patients in the control group were treated with olanzapine. The positive and negative symptom scales (PANSS) scores and the related indexes of diabetes before and after treatment were compared statistically. Results There was no significant difference in the scores of positive symptoms, negative symptoms and general mental symptoms between the two groups before treatment (P> 0.05). After treatment, the scores of positive symptoms, negative symptoms and general mental symptoms of the observation group were lower than those of the control group, The differences were statistically significant (P <0.05). The fasting blood glucose, 2h postprandial blood glucose and glycosylated hemoglobin were not significantly different between the two groups before treatment (P> 0.05). After treatment, the fasting blood glucose, postprandial 2h glucose and glycosylated hemoglobin were lower in the observation group than those in the control group , The differences were statistically significant (P <0.05). Conclusions The application of ziprasidone in patients with early-stage schizophrenia complicated with diabetes mellitus is more exact and can significantly reduce the clinical symptoms, and will not affect the patient’s blood glucose level, which is superior to olanzapine treatment. It is worthy of clinical application and promotion Therapeutic drugs.